Introduction {#S0001}
============

Chronic lymphocytic leukemia (CLL) is the most common adult leukemic disorder in the Euro-American population \[[@CIT0001]\]. Recent years have brought several breakthroughs in prognostic assessment and the therapeutic approach. Indeed, mutation and/or deletion of p53 and immunoglobulin heavy chain variable region (IGHV) mutation status emerged as the most powerful markers which greatly improved evaluation of the individual patient\'s prognosis \[[@CIT0002], [@CIT0003]\]. With regard to treatment, the fludarabine, cyclophosphamide, and rituximab regimen (FCR) is considered the gold standard in treatment of physically fit CLL patients in first-line therapy as well as after relapse \[[@CIT0004], [@CIT0005]\]. Furthermore, several more therapeutic options are currently at hand for the first-line or relapsed/refractory setting, e.g., bendamustine, alemtuzumab, ofatumumab, or high-dose corticosteroids \[[@CIT0006]--[@CIT0009]\]. Allogeneic stem cell transplantation, the only curative treatment option in CLL, is currently almost exclusively performed using reduced-intensity conditioning. This, together with better supportive care, leads to a significant decrease in transplant-related morbidity and mortality \[[@CIT0010], [@CIT0011]\]. Finally, many new promising molecules such as ibrutinib, idelalisib, and obinutuzumab are currently undergoing testing within clinical trials \[[@CIT0012]\]. This article covers the practical aspects of diagnosis, prognostication, and treatment of CLL.

Diagnosis and initial work-up {#S0002}
=============================

Chronic lymphocytic leukemia is nowadays diagnosed most frequently in asymptomatic patients when leukocytosis with lymphocytosis is accidentally found in the blood count performed within routine check-ups by a general practitioner or before a scheduled operation. In contrast to other indolent lymphoproliferative disorders, diagnosis of CLL is based on examination of peripheral blood by complete blood count and flow cytometry \[[@CIT0013]\] ([Table I](#T0001){ref-type="table"}). Chronic lymphocytic leukemia typically shows a highly distinctive immunophenotype with positivity for CD5, CD19 and CD23. The flow cytometric diagnostic score for CLL \[[@CIT0014]\] is very helpful for differential diagnosis ([Table II](#T0002){ref-type="table"}). Neither bone marrow aspiration/biopsy nor lymph node biopsy is required for the diagnosis of CLL and should be performed only in case of diagnostic ambiguity. Initial work-up should comprise patient\'s history, physical examination (including liver, spleen and lymph node palpation and performance status) and basic laboratory tests (complete blood count, biochemistry including electrolytes, renal functions, liver tests, lactate dehydrogenase, and protein electrophoresis, direct antiglobulin test, serum immunoglobulins) as recommended by International Workshop on CLL (IWCLL) 2008 guidelines \[[@CIT0013]\]. In addition, it seems beneficial to use abdominal ultrasonography to detect possible retroperitoneal lymphadenopathy as it detects lymph nodes otherwise inaccessible to physical examination; presence of abdominal lymphadenopathy is associated with shorter time to treatment \[[@CIT0015], [@CIT0016]\].

###### 

Diagnostic criteria for chronic lymphocytic leukemia (CLL)

  -----------------------------------------------------------------------------------
  1\. B-lymphocytes in peripheral blood \> 5 × 10^9^/l
  2\. Less than 55% atypical lymphocytes (e.g., prolymphocytes) in peripheral blood
  3\. Typical immunophenotype
  -----------------------------------------------------------------------------------

###### 

Flow cytometry score for chronic lymphocytic leukemia (CLL) diagnosis. sIg -- surface immunoglobulin. Chronic lymphocytic leukemia cases typically have a score of 4--5; other indolent lymphomas usually have a score of 0--2

  Marker   Points     
  -------- ---------- ----------
  CD5      Positive   Negative
  CD23     Positive   Negative
  sIg      Weak       Strong
  CD79b    Weak       Strong
  FMC7     Negative   Positive

Prognostic evaluation {#S0003}
=====================

Clinical staging systems by Rai *et al*. \[[@CIT0017]\] and Binet *et al*. \[[@CIT0018]\] serve as the basis for assessment of prognosis in CLL ([Tables III](#T0003){ref-type="table"} and [IV](#T0004){ref-type="table"}). They are based on simple and widely available methods (physical examination, complete blood count). However, these systems cannot identify patients diagnosed in early stages (currently the majority of patients) who will rapidly progress and have an unfavorable prognosis. Therefore, further refinement of individual prognosis requires more detailed laboratory assessment. Many prognostic markers have been discovered since the 1990s but only a few are recommended in routine practice. Traditional prognostic parameters recommended for initial evaluation include lymphocyte doubling time and serum β~2~-microglobulin or thymidine kinase \[[@CIT0013]\]. With regard to newer parameters, cytogenetic aberrations detected by fluorescent in situ hybridization (FISH) are currently considered the most useful for clinical practice. In particular, 17p deletion \[[@CIT0019]--[@CIT0021]\] and/or p53 mutation \[[@CIT0022]\] are the most powerful factors conferring rapid progression, low sensitivity to treatment and short overall survival \[[@CIT0023]\]. Therefore, these two tests are desirable at least before initiation of first-line treatment; in addition, repeated testing before subsequent lines of treatment is recommended as patients with CLL may develop clonal evolution \[[@CIT0024]\]. An unmutated sequence for the immunoglobulin heavy chain variable region (IGHV) is also an independent predictor of shorter time to progression and overall survival; however, it is currently not recommended for widespread routine testing \[[@CIT0013]\]. Other parameters such as CD38 or ZAP-70 expression are currently recommended for clinical trials only. Recent studies suggest that novel mutations such as NOTCH1, SF3B1, and BIRC3 also have significant prognostic implications \[[@CIT0025]--[@CIT0027]\], but it is too early to incorporate them into routine use.

###### 

Rai staging. Modified three-stage system (1987) assigns low risk to stage 0, intermediate risk to stage I/II and high risk to stage III/IV

  Stage   Definition
  ------- -----------------------------------
  0       Lymphocytosis
  I       Lymphadenopathy
  II      Hepatomegaly and/or splenomegaly
  III     Anemia, hemoglobin \< 110 g/l
  IV      Thrombocytopenia \< 100 × 10^9^/l

###### 

Binet staging. Cervical, axillary, inguinal lymph nodes, liver and spleen are each counted as one area. Bilateral involvement is counted as one area

  Stage   Definition
  ------- -----------------------------------------------------------------------
  A       \< 3 involved areas
  B       ≥ 3 involved areas
  C       Anemia (hemoglobin \< 100 g/l) and/or thrombocytopenia \< 100 × 109/l

Indication for treatment {#S0004}
========================

It is widely accepted that treatment of CLL should only be initiated in the case of disease activity ([Table V](#T0005){ref-type="table"}) \[[@CIT0013]\]. Treatment is therefore usually indicated for advanced clinical stages (Rai III/IV or Binet C). Short lymphocyte doubling time should not be the only reason to initiate treatment in patients with mild leukocytosis (\< 30 × 10^9^/l). Other factors contributing to lymphocytosis or lymphadenopathy, especially infections, should be ruled out before commencing treatment. Importantly, though CLL patients may develop an extremely high lymphocyte count, the absolute number of lymphocytes itself is not an indication for treatment because leukostasis is very rare in CLL \[[@CIT0013]\].

###### 

International Workshop on CLL (IWCLL) indication criteria for treatment

  ----------------------------------------------------------------------------------------------------------------
  1\. Progressive bone marrow failure: development and/or worsening of anemia and/or thrombocytopenia

  2\. Massive (\> 6 cm below left costal margin) or progressive/symptomatic splenomegaly

  3\. Massive (\> 10 cm in largest diameter) or progressive/symptomatic lymphadenopathy

  4\. Progressive lymphocytosis with increase \> 50% in 2 months or lymphocyte doubling time \< 6 months

  5\. Autoimmune anemia and/or thrombocytopenia poorly responding to corticosteroids or other standard treatment

  6\. Systemic symptoms associated with CLL:\
   -- weight loss ≥ 10% in 6 months\
   -- significant fatigue (ECOG performance status ≥ 2, inability to work or to perform everyday activities)\
   -- fevers \> 38.0°C for ≥ 2 weeks without evidence of infection
  ----------------------------------------------------------------------------------------------------------------

Pretherapeutic assessment {#S0005}
=========================

Routine evaluation before commencement of treatment should include physical examination with assessment of organomegaly, performance status, complete blood count, biochemistry, serum immunoglobulins, and direct antiglobulin test \[[@CIT0013]\]. Determination of infection status, especially viral hepatitis A (anti-HAV antibodies IgG and IgM), B (HBs antigen, anti-HBc total and IgM), and C (anti-HCV), is also very important \[[@CIT0013]\]. As mentioned before, FISH testing for del 17p, del 11q, del 13q and trisomy 12 and analysis of p53 mutations are highly desirable. Patients with anemia and/or thrombocytopenia should undergo bone marrow aspirate/biopsy. Use of imaging methods (e.g. computed tomography -- CT) to assess abdominal lymphadenopathy is not generally recommended; however, it may refine pretherapeutic staging as well as evaluation of therapeutic response; abdominal ultrasonography is a cheap and readily available (though less sensitive) alternative to CT \[[@CIT0013], [@CIT0028]\]. Chest radiograph is recommended if CT is not performed \[[@CIT0013]\].

Chronic lymphocytic leukemia is mainly a disease of the elderly with median age at diagnosis between 65 and 72 years \[[@CIT0029]--[@CIT0032]\]. Therefore, it is very useful to assess patient\'s fitness and general condition and adjust the extent of diagnostic procedures and therapeutic goals accordingly. Biological age is far more useful than simple calendar age. Eastern Cooperative Oncology Group (ECOG) performance status is a suitable basic tool. Ideally, patients should be evaluated for functional capacity and comorbid conditions. One of the possibilities is the Cumulative Illness Rating Scale (CIRS) established by the German CLL Study Group \[[@CIT0033]\]. This system assesses number and severity of comorbidities in each of 13 organ systems. Patients with a cumulative CIRS score ≥ 7 are considered significantly comorbid. Assessment of renal function using creatinine clearance (most frequently calculated from serum creatinine using the Cockcroft-Gault formula) \[[@CIT0034]\] is very useful as most cytotoxic drugs (e.g. fludarabine, cyclophosphamide, chlorambucil a.o.) are excreted via kidneys and renal impairment is associated with increased hematological and infectious toxicity. Patients up to 70 (possibly 75) years of age with performance status 0-1, CIRS score ≤ 6, creatinine clearance ≥ 70 ml/min and no severe comorbidities (e.g., advanced cardiac failure, ischemic heart disease or chronic obstructive lung disease) represent ideal candidates for intensive treatment such as FCR.

Assessment of therapeutic response {#S0006}
==================================

Therapeutic response should be evaluated according to International Workshop on CLL (IWCLL) 2008 guidelines ([Table VI](#T0006){ref-type="table"}) \[[@CIT0013]\]. Achievement of a complete or partial response is considered beneficial for the patient. In the case of stable disease or progression, a subsequent line of therapy should be initiated.

###### 

International Workshop on CLL (IWCLL) criteria for therapeutic response

  ----------------------------------------------------------------------------------------------------------------------
  Parameter                  Complete response (CR)                Partial response (PR)      Progressive disease (PD)
  -------------------------- ------------------------------------- -------------------------- --------------------------
  Group A (tumor burden):                                                                     

   Lymphadenopathy           \< 1.5 cm                             ↓ by ≥ 50%                 ↑ by ≥ 50%

   Hepatomegaly              None                                  ↓ by ≥ 50%                 ↑ by ≥ 50%

   Splenomegaly              None                                  ↓ by ≥ 50%                 ↑ by ≥ 50%

   ALC                       \< 4 × 10^9^/l                        ↓ by ≥ 50%                 ↑ by ≥ 50%

   Bone marrow               Normocellular, \< 30% lymphocytes,\   ↓ infiltration by ≥ 50%\   
                             no B-cell infiltrates                 or B-cell infiltrates      

  Group B (hematopoiesis):                                                                    

   Platelets                 \> 100 × 10^9^/l                      \> 100 × 10^9^/l\          ↑ by ≥ 50%
                                                                   or ↑ by ≥ 50%              

   Hemoglobin                \> 110 g/l                            \> 110 g/l\                ↓ by ≥ 20 g/l
                                                                   or ↑ by ≥ 50%              

   ANC                       \> 1.5 × 10^9^/l                      \> 1.5 × 10^9^/l\          
                                                                   or ↑ by ≥ 50%              
  ----------------------------------------------------------------------------------------------------------------------

CR: All criteria A and B have to be met; patient has no clinical symptoms. PR: At least 2 criteria A and 1 of criteria B have to be met for duration of ≥ 2 months. PD: Any of the A or B criteria have to be met. Stable disease (SD): neither PR nor PD criteria are met. ANC -- absolute neutrophil count, ALC -- absolute lymphocyte count, Hb -- hemoglobin.

Choice of specific treatment regimen {#S0007}
====================================

It is highly recommended to enroll CLL patients in clinical trials whenever possible as this is the only way to further improve therapeutic efficacy.

First-line treatment {#S0008}
====================

Fludarabine, cyclophosphamide, and rituximab (FCR) is currently the standard for first-line treatment of fit patients. This was established by the German CLL8 phase III study, which randomized 408 untreated fit patients (CIRS ≤ 6, creatinine clearance ≥ 70 ml/min) between FC and FCR regimens. Therapy with FCR resulted in a significantly higher CR rate (44% vs. 22%, *p* \< 0.0001), longer progression-free survival (PFS; 65% vs. 45% without progression at 3 years, *p* \< 0.0001) and also longer overall survival (OS, 87% vs. 83% alive at 3 years, *p* = 0.01). There was a significant increase in severe (grade III/IV) neutropenia (34% vs. 21%, *p* \< 0.0001) but without significantly elevated occurrence of infections. Patients with del 17p and/or p53 mutation have typically lower response rates to FCR, but this regimen can still be used for first-line treatment outside clinical trials, as monotherapy with alemtuzumab in the same setting did not yield better efficacy \[[@CIT0035]\] and the combination of alemtuzumab and high-dose corticosteroids, the most effective approach for patients with defective p53 so far, has been reported only in a small number of untreated patients (*n* = 17) \[[@CIT0036]\].

Elderly/comorbid patients require a different approach, as the number and severity of comorbid conditions contribute to inferior tolerance of chemotherapy \[[@CIT0033]\]. In particular, full-dose fludarabine regimens in elderly patients may result in unacceptable toxicity \[[@CIT0037], [@CIT0038]\].

Chlorambucil (CLB) was introduced into CLL therapy in the 1950s \[[@CIT0039]\] but could be considered the backbone of treatment in frail patients until recently as no other regimens proved to be superior. Several dosing schedules of chlorambucil are possible, e.g.: 1) 0.4--0.8 mg/kg administered every 2 weeks (used by the German CLL Study Group, GCLLSG) \[[@CIT0035]\], 2) 10 mg/m^2^ days 1--7 repeated every 28 days \[[@CIT0006]\]. Overall response rate (ORR) and progression-free survival (PFS) ranged from 37% to 72% and 9 to 20 months, depending on the patient population. Complete responses are infrequent with CLB monotherapy. The German CLL5 study showed that although fludarabine induced significantly more overall responses (ORR) and complete remissions (CR) than CLB in untreated patients ≥ 65 years in (ORR: 72% vs. 51%, *p* = 0.003; CR: 7% vs. 0%, *p* = 0.011), it did not translate into longer progression-free (median: 19 vs. 18 months, *p* = 0.7) or overall survival (median: 46 vs. 64 months, *p* = 0.15) \[[@CIT0040]\]. Recently, two randomized studies published in abstract form showed for the first time significant improvement over CLB monotherapy. The German CLL11 study randomized 589 untreated patients with significant comorbidities (cumulative CIRS score ≥ 7 and/or creatinine clearance \< 70 ml/min) in 1 : 2 : 2 fashion between CLB monotherapy (0.5 mg/kg days 1 and 15, for a maximum of 6 cycles), CLB + rituximab (R-CLB, 375 mg/m^2^ *i.v*. day 1, cycle 1; 500 mg/m^2^ day 1 in cycles 2--6), and CLB + obinutuzumab (GA-101), a novel humanized type II glycoengineered anti-CD20 antibody with enhanced direct cell killing and antibody-dependent cytotoxicity (G-CLB, 100 mg *i.v*. day 1, 900 mg *i.v*. day 2, 1000 mg *i.v*. days 8 and 15 of cycle 1, 1000 mg *i.v*. day 1 in cycles 2--6). Both combination regimens proved significantly superior to CLB monotherapy in terms of CR rate (R-CLB: 8%; G-CLB: 22%, CLB: 0%) and PFS (R-CLB: 15.7 months; G-CLB: 23 months; CLB: 10.9 months, *p* \< 0.0001). In addition, patients treated with G-CLB had significantly longer overall survival in comparison to CLB alone (median OS not reached in either group, death rate 9% vs. 20%, *p* = 0.002). Differences in CR rate and PFS were also significantly better with G-CLB vs. R-CLB. Obinutuzumab caused more severe infusion-related toxicity than rituximab (21% vs. 4%) and more frequent severe neutropenia than rituximab or CLB (34% vs. 25% vs. 15%), but this did not translate into an increased rate of severe infections (6% vs. 8% vs. 11%) \[[@CIT0041]\]. Based on these results, obinutuzumab was approved for first-line treatment of CLL in comorbid patients. Combination of CLB and ofatumumab, a fully human anti-CD20 antibody with enhanced complement-dependent cytotoxicity, was compared against CLB monotherapy in another large phase III randomized study. A total of 447 untreated CLL patients older than 65 years were randomized between CLB (10 mg/m^2^ days 1--7 repeated every 28 days for a maximum of 12 cycles) and CLB + ofatumumab (O-CLB, 300 mg *i.v*. day 1, 1000 mg day 8 cycle 1, 1000 mg *i.v*. day 1, in cycles 2--12, cycles repeated every 28 days). The O-CLB combination achieved significantly more ORR/CR (82/14% vs. 69/1%, *p* \< 0.001) as well as longer PFS (22.4 months vs. 13.1 months, *p* \< 0.001) with no unexpected toxicity. Serious infusion-related reactions occurred in 10% \[[@CIT0042]\]. Taken together, these two studies indicate that combination of CLB and anti-CD20 monoclonal antibody is becoming a new standard of care in untreated comorbid CLL patients.

Bendamustine is a unique cytostatic agent with combined properties of an alkylating agent and purine analog, originally developed in the 1960s in the former East Germany. An international phase III study randomized 305 untreated CLL patients between bendamustine (100 mg/m^2^ *i.v*. days 1--2 repeated every 28 days) and chlorambucil (0.8 mg/kg days 1 and 15, repeated every 28 days). Bendamustine showed significantly higher OR/CR (68/30% vs. 39/2%) as well as PFS (21.7 vs. 9.3 months) \[[@CIT0006]\]. These results led to approval of bendamustine for the first-line treatment of CLL patients ineligible for FCR. Bendamustine has also been successfully combined with rituximab (BR regimen) in a phase II trial by GCLLSG. A total of 117 patients with median age 64 years (26% older than 70) received bendamustine 90 mg/m^2^ *i.v*. days 1--2, repeated every 4 weeks plus rituximab in a standard CLL dose for up to 6 cycles. ORR/CR rates were 88/23%; median event-free survival was 27 months; severe neutropenia and infections developed in 20% and 8% only \[[@CIT0043]\]. BR is currently being compared with FCR in untreated fit patients within the German phase III randomized study CLL10.

Dose-reduced fludarabine regimens represent a logical approach with the goal of reduced toxicity and preserved efficacy. Several single-center studies reported promising efficacy and manageable toxicity of low-dose fludarabine-based combinations \[[@CIT0044]\]. The low-dose FCR regimen (fludarabine 12 mg/m^2^ *i.v*. or 20 mg/m^2^ orally days 1--3, cyclophosphamide 150 mg/m^2^ *i.v*./orally days 1--3, rituximab standard CLL dose, repeated every 28 days) used by the Czech CLL Study Group reported very good efficacy in elderly/comorbid CLL patients in treatment of first-line (*n* = 102; ORR: 79%; median PFS: 20 months) as well as relapsed/refractory disease (*n* = 97; ORR: 64%; median PFS: 15 months). Toxicity was acceptable (severe neutropenia, 57 and 49%; severe infections, 14 and 18% of patients) \[[@CIT0045]\].

Treatment of relapse {#S0009}
====================

Identically to first-line treatment, relapsed CLL should only be treated when indications for treatment are fulfilled ([Table V](#T0005){ref-type="table"}). Patients with relapsed CLL may be retreated with the same regimen used in the previous line of treatment if a therapeutic response was achieved and the duration of response exceeded 12 months for monotherapy protocols or 24 months for fludarabine combinations (e.g., FC, FCR) \[[@CIT0013]\]. FCR is the most suitable second-line regimen for patients who are not pretreated with rituximab or fludarabine combinations, as the randomized REACH study showed a higher CR rate (24 vs. 13%, *p* \< 0.001) and longer PFS (30.6 vs. 20.6 months, *p* \< 0.001) in comparison to FC, without significantly increased infection frequency \[[@CIT0005]\].

Refractory chronic lymphocytic leukemia {#S0010}
=======================================

Treatment of refractory CLL represents one of the most challenging situations in hematological oncology. Despite impressive efficacy of fludarabine-based chemoimmunotherapy, 5--10% of patients will not respond to first-line treatment and others will become fludarabine-refractory in subsequent lines of therapy.

The humanized monoclonal anti-CD52 antibody alemtuzumab is indicated in fludarabine-refractory patients. Overall response rate can be expected between 30% and 40%, but complete responses are rare and response duration usually does not exceed 12 months \[[@CIT0007], [@CIT0046]\]. In addition, alemtuzumab causes severe and long-lasting immune suppression due to depletion of B and T cells; therefore, combined antimicrobial prophylaxis and cytomegalovirus monitoring are compulsory \[[@CIT0047]\] and the risk : benefit ratio must be carefully assessed. Double refractory patients (i.e., refractory to fludarabine and alemtuzumab) or fludarabine-refractory with bulky lymphadenopathy (thus not good candidates for alemtuzumab) have an extremely unfavorable prognosis \[[@CIT0048]\].

The German CLL Study Group reported results of bendamustine + rituximab (BR) combination in 78 relapsed/refractory patients (median age: 66.5 years; median previous treatment lines: 2; 28% fludarabine-refractory; 18% with 17p deletion). The bendamustine dose was 70 mg/m^2^ *i.v*. days 1--2, repeated every 4 weeks. The ORR/CR rate was 59/9%, including 46% in fludarabine-refractory but only 7% in del 17p. Median PFS was 15 months; severe neutropenia and infections developed in 23% and 13% only \[[@CIT0049]\].

Ofatumumab is the only agent approved for the treatment of double-refractory CLL owing to results of a large international phase II trial which treated 206 heavily pretreated patients (double refractory, *n* = 95; bulky fludarabine refractory, *n* = 11, median age was 64 years, median previous therapies, 5 and 4). Treatment consisted of 8 weekly *i.v*. infusions (1 × 300 mg + 7 × 2000 mg) followed by four monthly infusions of 2000 mg. ORR was 51% and 44%, median PFS 5.5 months and median OS 14.2 and 17.4 months. Infusion-related side effects were seen in 63% of patients, but 95% of these were grade I--II. Severe infections developed in 24% of patients \[[@CIT0008]\].

Combination of high-dose corticosteroids with monoclonal antibodies emerged as a promising option for relapsed/refractory CLL. Rituximab with high-dose methylprednisolone (HDMP, 1 g/m^2^ *i.v*. days 1--5) was effective but relatively toxic (steroid diabetes, fluid retention, severe infections up to 50%, early deaths on treatment) in several small studies \[[@CIT0009], [@CIT0050]--[@CIT0054]\]. Following promising results of a substantially lower dose of dexamethasone (40 mg orally days 1--4 combined with rituximab) \[[@CIT0052]\], a two-center retrospective study reported results in 54 patients with relapsed/refractory CLL (82% pretreated with fludarabine and 29% with alemtuzumab). Dexamethasone was given 40 mg orally on days 1--4 and 10--13; rituximab was administered on day 1 and cycles repeated every 21 days (*n* = 25) or weekly with cycles repeated every 28 days (*n* = 29). ORR/CR was 71/4 and 62/21%; median PFS was 6.9 and 6.9 months. Three patients proceeded successfully to nonmyeloablative allogeneic stem cell transplantation. Serious infections occurred in 32% of patients \[[@CIT0055]\]. [Table VII](#T0007){ref-type="table"} summarizes the most frequently used regimens for treatment of CLL.

###### 

Most frequently used therapeutic regimens for chronic lymphocytic leukemia (CLL)

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Protocol                        Schedule
  ------------------------------- ------------------------------------------------------------------------------------------------------------------------
  Chlorambucil                    10 mg/m^2^ orally on days 1--7, repeated every 4 weeks\
                                  0.4--0.8 mg/kg orally on day 1, repeated every 2 weeks

  FCR                             F: 40 mg/m2 orally or 25 mg/m^2^ *i.v*. on days 1--3, C: 250 mg/m^2^ orally/*i.v*. on days 1--3,\
                                  R: 500 mg/m^2^ (375 mg/m^2^ in 1^st^ cycle) *i.v*. on day 1, repeated every 4 weeks

  Bendamustine                    100 mg/m^2^ *i.v*. on days 1--2, repeated every 4 weeks

  BR -- untreated CLL             B: 90 mg/m^2^ *i.v*. on days 1--2, R: 500 mg/m^2^ (375 mg/m^2^ in 1^st^ cycle) *i.v*. on day 1, repeated every 4 weeks

  BR -- relapsed/refractory CLL   B: 70 mg/m^2^ *i.v*. on days 1--2, R: 500 mg/m^2^ (375 mg/m^2^ in 1^st^ cycle) *i.v*. on day 1, repeated every 4 weeks

  Alemtuzumab                     30 mg *i.v*./subcutaneously 3 x weekly for 12 weeks (dose escalation 3--10--30 mg in 1^st^ week)

  Ofatumumab                      300 mg *i.v*. on day 1, then 7 infusions of 2000 mg *i.v*. weekly, then 4 infusions of 2000 mg *i.v*. monthly
  --------------------------------------------------------------------------------------------------------------------------------------------------------

F -- fludarabine, C -- cyclophosphamide, R -- rituximab, B -- bendamustine.

Allogeneic stem cell transplantation {#S0011}
====================================

Allogeneic stem cell transplantation (alloSCT) currently represents the only potentially curative treatment option in patients with CLL. Reduced intensity conditioning (RIC) using lower doses of cytotoxic agents is nowadays almost exclusively performed because of significantly lower non-relapse mortality than myeloablative conditioning; the graft-versus-leukemia (GVL) effect is very well characterized in CLL. Acute and chronic graft-versus-host disease remains a significant problem \[[@CIT0010], [@CIT0011]\]. Autologous transplantation has been abandoned in CLL as it did not convey any advantage over chemoimmunotherapy \[[@CIT0056]\]. It is essential that every patient with a highly unfavorable disease course should be assessed regarding the possibility of alloSCT. Indications for alloSCT according to European Blood and Marrow Transplantation (EBMT) are listed in [Table VIII](#T0008){ref-type="table"}. Ideally, alloSCT in CLL patients should be performed within prospective clinical trials \[[@CIT0057]\].

###### 

European Research Initiative for Chronic lymphocytic leukemia (ERIC) indication criteria for allogeneic transplantation in chronic lymphocytic leukemia (CLL)

  -------------------------------------------------------------------------------
  Allogeneic stem cell transplantation is a reasonable option for poor risk CLL
  -------------------------------------------------------------------------------
  1\. Purine analog-refractory CLL

  2\. Short response duration to previous therapy:\
   ≤ 12 months for purine analog monotherapy\
    ≤ 24 months for combination therapy (e.g., FCR)

  3\. Deletion/mutation of p53 with indication for treatment
  -------------------------------------------------------------------------------

Minimal residual disease {#S0012}
========================

A seminal study using the monoclonal anti-CD52 antibody alemtuzumab demonstrated that patients who achieved eradication of minimal residual disease (i.e., negativity of highly sensitive methods such as multicolor flow cytometry or PCR with patient-specific primers) had not only significantly longer PFS but also overall survival (OS) \[[@CIT0013]\]. These results were recently corroborated by the results of the randomized CLL-8 study (FCR vs. FC in untreated fit patients) \[[@CIT0004]\]. The study identified minimal residual disease (MRD) measured by four-color flow cytometry as an independent predictor of PFS and OS. Patients who achieved MRD ≤ 10^--4^ had the best outcome irrespective of treatment arm \[[@CIT0058]\]. While MRD in CLL is a very powerful predictive factor and MRD negativity will probably be used in clinical trials as a surrogate marker for PFS, MRD is not yet recognized as a compulsory parameter in routine practice.

Novel agents {#S0013}
============

Recent years have witnessed an explosion of clinical studies using novel targeted drugs in CLL. The two most promising agents appear to be ibrutinib, an inhibitor of Bruton tyrosine kinase, and idelalisib, an inhibitor of phosphatidyl-3-inositol kinase (PI3K) delta. Both of these agents target downstream B-cell receptor signaling pathways, are orally available and are designed for prolonged administration until CLL progression or unacceptable toxicity. Ibrutinib achieved excellent results in a phase 1b/2 trial \[[@CIT0059]\] and subsequently demonstrated superiority over ofatumumab in terms of better ORR, PFS and OS in a randomized trial in heavily pretreated CLL patients \[[@CIT0060]\]. Idelalisib in combination with rituximab showed superior ORR, PFS as well as OS over rituximab monotherapy in relapsed/refractory patients deemed unfit for chemotherapy \[[@CIT0061]\]. These studies resulted in recent approval of ibrutinib and idelalisib for the treatment of CLL. Further agents in advanced phases of clinical trials include the bcl-2 inhibitor venetoclax (GDC-0199, ABT-199), the immunomodulating agent lenalidomide, the PI3K inhibitor IPI-145, and modified autologous T-cells with chimeric antiCD19 antigen (CARs) ([Table IX](#T0009){ref-type="table"}) \[[@CIT0062]\].

###### 

Novel agents for the treatment of chronic lymphocytic leukemia (CLL)

  Agent                            Mechanism of action                              Phase of development
  -------------------------------- ------------------------------------------------ ----------------------
  Obinutuzumab (GA-101)            Glycoengineered type II anti-CD20 antibody       Approved; phase III
  Ibrutinib (PCI-32765)            Bruton tyrosine kinase inhibition                Approved; phase III
  Idelalisib (GS-1101)             Phosphatidylinositol-3-kinase delta inhibition   Approved; phase III
  Lenalidomide                     Complex -- microenvironment                      Phase III
  Venetoclax (GDC-0199, ABT-199)   Bcl-2 inhibition                                 Phase III
  IPI-145                          Phosphatidylinositol-3-kinase inhibition         Phase II/III
  CAR T-cells                      T-lymphocytes with chimeric anti CD19 receptor   Phase II

Conclusions {#S0014}
===========

We are entering a completely new era in prognostication and treatment of CLL. While diagnostic criteria will probably not change very soon, further refinement of individual patient prognosis is very likely. The indication for treatment is still based solely on clinical activity of CLL. Currently running clinical trials will provide information whether early treatment of patients with unfavorable prognosis confers clinical benefit. Chemoimmunotherapy can be currently regarded as the gold standard for fit as well as comorbid patients. Novel targeted agents have promising activity in relapsed/refractory disease where prognosis is still poor. Therefore, achievement of the most important therapeutic goals -- prolongation of overall survival and improvement in quality of life -- can be expected in a growing number of CLL patients in the near future.
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